• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Quotient Sciences

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    PCI Pharma Services

    Almac Group

    Emergent BioSolutions

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

    Work together to develop and commercialize CHI’s novel dry-powder inhaler product.

    Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
    The αeolus technology platform has been designed to promote greater delivery efficiency and consistency that is independent of patient effort, potentially leading to dose sparing.
    Related CONTENT
    • AJILITY: Intelligent Drug Product Manufacturing
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • Agilex Biolabs Acquires TetraQ for APAC Expansion Plans
    • Imvax Appoints Sean Hemingway Chief Operating Officer
    • Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    Charles Sternberg, Assistant Editor04.07.21
    Kindeva Drug Delivery L.P. and Cambridge Healthcare Innovations Limited (CHI) have entered into a collaboration to develop and commercialize CHI’s αeolus dry-powder inhaler (DPI) platform technology.
     
    The collaboration will leverage Kindeva’s product development, regulatory affairs, and manufacturing capabilities in tandem with CHI’s DPI technology and device development expertise. To accelerate platform and product development, Kindeva and CHI will evaluate a range of drugs for the αeolus platform.
     
    This initial work will inform development programs undertaken in partnership with biopharmaceutical companies. Additionally, the initial drugs evaluated, subject to all required regulatory approvals, could become products to treat a range of respiratory diseases. The αeolus technology platform could also be used for the systemic delivery of drugs to the lungs, addressing a broader range of conditions.
     
    About CHI’s αeolus Technology
     
    CHI is a medical device company with expertise in inhalation drug delivery, designing and developing devices that enhance treatment for patients suffering from asthma, COPD, and other chronic diseases. The αeolus technology platform has been designed to promote greater delivery efficiency and consistency that is independent of patient effort, potentially leading to dose sparing. As a true platform technology, αeolus-driven devices may be available in multiple variants that utilize the same core technology. These variants include single-use, reusable, and multi-dose devices, which have the potential to incorporate SMART electronics and enable connectivity.
     
    Kindeva is a global contract development and manufacturing organization (CDMO) that has a legacy of solving complex drug delivery challenges across a range of delivery formats, including inhalation. This collaboration with CHI represents a natural extension of Kindeva’s DPI experience, building on significant prior work and strong global capabilities.
     
    “With their unrivalled history and expertise in inhaled drug-delivery, Kindeva is the ideal partner to bring this revolutionary technology to the market,” said David Harris, co-founder and chief technology officer of CHI. “We’re excited to be working together to bring pharmaceutical customers’ products to market faster and at significantly reduced risk, and to offer the unique opportunity to deliver therapies beyond the reach of existing inhalation technology. We’re looking forward to redefining what inhalers can achieve.”
     
    “We are excited to partner with CHI to develop and commercialize a truly novel DPI technology platform,” said Aaron Mann, CEO of Kindeva. “As leaders in inhalation product development, Kindeva understands that the industry must embrace the development of patient-centered technologies in order to meaningfully improve the way patients are treated. The αeolus technology is designed to avoid many of the drawbacks of existing inhalation technology, addressing the need for efficiency, simplicity, and consistency of delivery, which lead to a more robust patient experience.”
     
    Under the agreement, Kindeva will lead business development and product development activities, including toxicology, process development, and clinical design, while CHI leads technology and device development.
     
    The parties expect that their collaboration will lead to the development of multiple commercial products, with confidential discussions already underway with several global biopharmaceutical companies.
    Related Searches
    • Drug Development
    • Drug Delivery
    Suggested For You
    AJILITY: Intelligent Drug Product Manufacturing AJILITY: Intelligent Drug Product Manufacturing
    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans Agilex Biolabs Acquires TetraQ for APAC Expansion Plans
    Imvax Appoints Sean Hemingway Chief Operating Officer Imvax Appoints Sean Hemingway Chief Operating Officer
    Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment
    PharmParts – This Makes Sense! PharmParts – This Makes Sense!
    Recro Pharma Expands Business Development Team Recro Pharma Expands Business Development Team
    LabVantage Solutions Expands and Improves its Portfolio LabVantage Solutions Expands and Improves its Portfolio
    Charles River Acquires Retrogenix Charles River Acquires Retrogenix
    What Will Change at FDA for 2021? What Will Change at FDA for 2021?
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    RBQM Comes of Age: COVID as a Catalyst for Change RBQM Comes of Age: COVID as a Catalyst for Change
    Piramal Pharma to Acquire Indian API Manufacturer Hemmo Piramal Pharma to Acquire Indian API Manufacturer Hemmo
    SK Capital Completes Acquisition of BFS from Catalent Pharma Solutions SK Capital Completes Acquisition of BFS from Catalent Pharma Solutions

    Related Breaking News

    • Analytical Services | Breaking News | Clinical Trial Materials | Drug Development | Industry News
      Ascendia Pharmaceuticals Poised for Expansion

      Ascendia Pharmaceuticals Poised for Expansion

      CDMO secures growth equity investment from Signet Healthcare Partners.
      Tim Wright, Editor, Contract Pharma 04.09.21

    • Breaking News | Clinical Trials | Drug Development | Industry News
      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.
      Kristin Brooks 04.06.21

    • Breaking News | Clinical Trials | CRO News | Drug Development
      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
      Kristin Brooks 04.06.21


    • Breaking News | Drug Development
      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Expands its oncology leadership capabilities in the U.S.
      Charles Sternberg, Assistant Editor 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.
      Kristin Brooks 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.
      Kristin Brooks 03.30.21


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Facilities | Industry News
      Chime Biologics Expands CDMO Capabilities

      Chime Biologics Expands CDMO Capabilities

      Completes $190 million financing round to accelerate capacity expansion.
      Tim Wright, Editor, Contract Pharma 03.29.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.
      Tim Wright, Editor, Contract Pharma 03.25.21

    • Breaking News | Drug Development | Facilities | Industry News | Parenterals
      Eisai Begins Construction of New Injection/Research Building

      Eisai Begins Construction of New Injection/Research Building

      To accommodate expanded drug discovery targets and new modalities such as antibodies, ADCs, and nucleic acid drugs.
      Kristin Brooks 03.22.21


    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Evotec, Takeda Enter Multi-RNA Target Alliance

      Evotec, Takeda Enter Multi-RNA Target Alliance

      To discover and develop small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
      Kristin Brooks 03.22.21

    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      Gilead, Novo Nordisk Expand NASH Alliance

      Gilead, Novo Nordisk Expand NASH Alliance

      Phase II trial to investigate Novo’s semaglutide and a combination of Gilead’s cilofexor and firsocostat, alone and in combination in cirrhosis due to NASH.
      Kristin Brooks 03.18.21

    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy

      Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy

      Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2.
      Kristin Brooks 03.16.21


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Selexis, Pandion Enter Antibody Service Agreement

      Selexis, Pandion Enter Antibody Service Agreement

      Pandion will leverage Selexis’ SUREtechnology Platform to advance an antibody targeting autoimmune and inflammatory diseases.
      Kristin Brooks 03.16.21

    • APIs | Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
      PhaseBio and BioVectra Enter into Supply Agreement

      PhaseBio and BioVectra Enter into Supply Agreement

      To support development and commercialization of bentracimab.
      Tim Wright 03.11.21

    • Breaking News | Collaborations & Alliances | Drug Development
      Selexis SA and BITT Enter Service Agreement

      Selexis SA and BITT Enter Service Agreement

      Will develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 oncology candidate.
      Charles Sternberg, Assistant Editor 03.10.21

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login